Palatin Technologies, Inc. (PTN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.2853 |
| Open | 0.2805 |
| Bid | 0.3000 x 3000 |
| Ask | 0.3034 x 1000 |
| Day's Range | 0.2790 - 0.3050 |
| 52 Week Range | 0.2500 - 0.9600 |
| Volume | |
| Avg. Volume | 681,337 |
| Market Cap | 69.404M |
| Beta (5Y Monthly) | 1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1550 |
| Earnings Date | Feb 15, 2022 - Feb 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced preliminary fourth quarter 2022 Vyleesi® product sales. Vyleesi is the first and only as-needed treatment approved by the U.S. Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
- Zacks
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
- Zacks
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 0% and 62.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
